Succinylated Human Serum Albumin (Suc-HSA) for HIV-1 Infection
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00128063 |
Recruitment Status :
Completed
First Posted : August 9, 2005
Last Update Posted : April 24, 2007
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
HIV Infections | Drug: succinylated human serum albumin | Phase 1 Phase 2 |
This is a single centre, single arm study. Subjects will receive 5 consecutive daily doses of Suc-HSA at a dose of 10 mg/kg on days 0, 1, 2, 3 and 4 on the Special Investigation Unit (SIU), with a safety follow up on the SIU for 4 hours on day 1 and 2 hours on the next days. There will be follow-up visits on week 1, 2, 4 and 12. Standard safety parameters (physical examination, clinical symptoms, laboratory hematology and biochemistry) will be followed until week 12. Plasma HIV-1 RNA and CD4+/CD8+ cell counts will be assessed at every visit. Plasma drug levels (trough and peak) will be measured from baseline until week 2.
6 patients will be included in this study as described in this protocol amendment.
Eligible subjects are chronic HIV-1 infected patients who have never been treated with antiretroviral treatment and for whom there is no need to start antiretroviral treatment.
Test Product: Suc-HSA, a candidate HIV-1 fusion inhibitor.
Duration of treatment: 5 days
Criteria for evaluation:
- Safety: symptoms, signs at physical examination, standard hematology and chemistry laboratory parameters- Efficacy: changes in plasma HIV-1 RNA and CD4+ T cell count
- Pharmacokinetics: plasma levels of Suc-HSA: Cmin, Cmax and AUC
Study Type : | Interventional (Clinical Trial) |
Enrollment : | 6 participants |
Allocation: | Non-Randomized |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase 1 & 2, Randomized Open-Label Study to Evaluate the Pharmacokinetics, Safety and Antiretroviral Activity of Succinylated Human Serum Albumin (Suc-HSA) in Treatment Naïve HIV-1 Infected Subjects |
Study Start Date : | August 2005 |
Actual Study Completion Date : | June 2006 |

- To evaluate the pharmacokinetic behavior of Suc-HSA after consecutive daily i.v. doses.
- To evaluate the safety and tolerability and the antiretroviral and immunological effects of consecutive daily i.v. doses of Suc-HSA.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patient is ≥ 18 years of age;
- Voluntarily signed informed consent;
- Patient has a proven HIV-1 infection (with positive antibodies against HIV-1 and a detectable plasma HIV-1 RNA);
- Patient is HIV-1 treatment naïve;
- CD4+ T-cell count ≥ 350 x 10^6/L;
- Plasma HIV-1 RNA level at screening visit of at least 5.000 copies/ml, and not varying more than ± 0.5 log10 copies during the preceding 6 month period;
- Patient was participant in part 1 of the original Suc-HSA study (protocol no. 2003-002, version 2.4, dated 18 November 2003) and the administration of Suc-HSA occurred more than 8 weeks ago, OR patient was not participant in this study;
-
Patient is one of the following:
- not heterosexually active, OR
- a heterosexually active female, agreeing to use an effective method of contraception with her partner (combined oral contraceptive pill; injectable contraceptive; intrauterine contraceptive device (IUCD); consistent use of condoms if using these; physiological or anatomical sterility in herself or her partner) from 14 days prior to the first administration of study medication until 4 months after the last, and willing to undergo urine pregnancy tests prior to the first and last administration, OR
- a heterosexually active male, agreeing to use an effective method of contraception with his partner from the day of the first administration until 4 months after the last administration.
Exclusion Criteria:
- History of an AIDS defining event;
- Use of antiretroviral or immunomodulatory therapy;
- Any reason to start antiretroviral therapy at the time of enrolment or which is expected to occur during the course of the study at the time of enrolment;
- Presence of active, replicating hepatitis B and/or C virus co-infection;
- ASAT and/or ALAT > 3 times upper limit of normal (ULN) (AIDS Clinical Trials Group [ACTG] toxicity scale);
- Serum creatinine measuring > 1.5 x ULN;
- Total bilirubin > 2x ULN;
- Neutropenia (absolute neutrophil count < 1000/mm3);
- Presence of any clinically significant disease or findings during screening, that in the opinion of the investigator could compromise the safety of the subject;
- Patient is female and (willing to become) pregnant or breast-feeding;
- Any other condition which, in the opinion of the investigator, may interfere with the evaluation of the study objectives.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00128063
Netherlands | |
Academic Medical Center, University of Amsterdam | |
Amsterdam, NH, Netherlands, 1105AZ |
Study Chair: | Joep MA Lange, MD PhD | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | |
Principal Investigator: | Jan Prins, MD PhD | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) |
ClinicalTrials.gov Identifier: | NCT00128063 |
Other Study ID Numbers: |
04-IAT-0047 |
First Posted: | August 9, 2005 Key Record Dates |
Last Update Posted: | April 24, 2007 |
Last Verified: | April 2007 |
HIV-1 succinylated human serum albumin Treatment Naive |
Infections |